Bianca N. Islam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bianca N. Islam has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Darren D. Browning
Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA 30912, USA
5 shared publications - Fabio Cominelli
Department of Medicine, Case Western Reserve University School of Medicine
4 shared publications - Theresa T. Pizarro
Department of Pathology, Case Western Reserve University School of Medicine , Cleveland, OH
4 shared publications - Kimberly Curry
Case Western Reserve University, Cleveland, Ohio, USA
3 shared publications - Neha Khandekar
Digestive Health Research Institute; Division of Gastroenterology and Liver Diseases, Case Western Reserve University, Cleveland, Ohio, USA
3 shared publications - Alka Tomar
Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
2 shared publications
Latest Publications
- 10 November 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Cellular therapies and immune reprogramming in inflammatory bowel disease: lessons learned and the promise of CAR T-cell therapy
Despite major therapeutic advances, inflammatory bowel disease (IBD) remains incurable, and many patients experience primary non-response, secondary loss of response, progressive bowel damage, or lifelong dependence on immunomodulatory therapy. Cellular immunotherapies offer the possibility of moving beyond chronic immune suppression toward durable immune reprogramming. Earlier approaches in IBD, including hematopoietic stem cell transplantation, mesenchymal stem cells, and regulatory T-cell–based therapies, have provided important proof-of-concept but have been limited by toxicity, inconsistent efficacy, local rather than systemic effects, or unresolved manufacturing and durability challenges. Chimeric antigen receptor (CAR) T-cell therapy represents the next-generation strategy that combines potent immune remodeling with antigen-specific targeting. Initially developed for hematological malignancies, CAR T cells have recently shown striking efficacy in refractory autoimmune diseases, particularly through CD19-mediated depletion of B-lineage cells and induction of drug-free remission. In ulcerative colitis, renewed interest in B cells has been driven by evidence of plasmablast expansion, IgG-skewed humoral responses, anti-integrin αvβ6 autoantibodies, and the limitations of conventional anti-CD20 depletion. The first reported case of multidrug-resistant ulcerative colitis treated with CD19 CAR T cells demonstrated rapid clinical, biochemical, endoscopic, and histological remission, providing proof-of-concept for deep B-cell targeting in IBD. However, major uncertainties remain, including long-term durability, relapse after B-cell reconstitution, safety, cost, feasibility, and the risk of CAR T-associated gastrointestinal toxicity. Prospective trials with mechanistic mucosal monitoring are now needed to define the therapeutic potential and appropriate positioning of CAR-based strategies in IBD.
- 10 November 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Cellular therapies and immune reprogramming in inflammatory bowel disease: lessons learned and the promise of CAR T-cell therapy
Despite major therapeutic advances, inflammatory bowel disease (IBD) remains incurable, and many patients experience primary non-response, secondary loss of response, progressive bowel damage, or lifelong dependence on immunomodulatory therapy. Cellular immunotherapies offer the possibility of moving beyond chronic immune suppression toward durable immune reprogramming. Earlier approaches in IBD, including hematopoietic stem cell transplantation, mesenchymal stem cells, and regulatory T-cell–based therapies, have provided important proof-of-concept but have been limited by toxicity, inconsistent efficacy, local rather than systemic effects, or unresolved manufacturing and durability challenges. Chimeric antigen receptor (CAR) T-cell therapy represents the next-generation strategy that combines potent immune remodeling with antigen-specific targeting. Initially developed for hematological malignancies, CAR T cells have recently shown striking efficacy in refractory autoimmune diseases, particularly through CD19-mediated depletion of B-lineage cells and induction of drug-free remission. In ulcerative colitis, renewed interest in B cells has been driven by evidence of plasmablast expansion, IgG-skewed humoral responses, anti-integrin αvβ6 autoantibodies, and the limitations of conventional anti-CD20 depletion. The first reported case of multidrug-resistant ulcerative colitis treated with CD19 CAR T cells demonstrated rapid clinical, biochemical, endoscopic, and histological remission, providing proof-of-concept for deep B-cell targeting in IBD. However, major uncertainties remain, including long-term durability, relapse after B-cell reconstitution, safety, cost, feasibility, and the risk of CAR T-associated gastrointestinal toxicity. Prospective trials with mechanistic mucosal monitoring are now needed to define the therapeutic potential and appropriate positioning of CAR-based strategies in IBD.
- Open Access
- 3 February 2026
- Published by BMJ in Gut Science
- Vol. 1 (1) , e000008
Epithelial and stromal remodelling in murine Crohn’s disease-like ileitis
Background: Inflammatory bowel disease is characterised by progressive epithelial, immune and stromal dysfunction. Human datasets yield important insights yet are inherently descriptive, requiring animal models for in vivo mechanistic interrogation. The SAMP1/YitFc (SAMP) mouse model develops spontaneous Crohn’s disease (CD)-like ileitis, allowing for the controlled manipulation of pathophysiological pathways. Objective: To define cell-specific disease-associated transcriptional changes and their translational relevance, we profiled inflamed SAMP ilea by single-nucleus RNA-sequencing (snRNA-seq) and compared identified programmes with human IBD single-cell RNA-seq datasets. Design: We performed whole-ileum snRNA-seq on SAMP (n=4) and control AKR/J (n=3) mice using the gut-optimised CitraPrep protocol, generating 58 349 high-quality nuclei across epithelial, immune and stromal lineages. We corroborated SAMP-associated changes with immunofluorescent staining, western blotting, spatial transcriptomic and human single-cell RNA-seq data. Results: We observed a primary type 2 immune phenotype in SAMP compared with AKR mice, but most transcriptional changes occurred in stromal and epithelial, not immune, cells. Stromal remodelling included increased fibroblast-derived Igf1 . In SAMP epithelium, expansion of tuft cells and emergence of SAMP-specific Pcsk6+ crypt enterocytes were observed and confirmed in patients with CD. Finally, we identified cross-compartmental changes in cell–cell signalling, including enterocyte-to-type three innate lymphoid cell communication and enhanced global Igf1 signalling. These features recapitulate both known and novel characteristics of CD, thereby extending our understanding of disease-associated multicellular networks. Conclusion: This atlas of ileitis-prone SAMP mice provides a high-resolution resource for dissecting conserved and novel mechanisms of inflammation and tissue remodelling. In this study, we uncover disease-associated transcriptional changes conserved in human CD, presenting a translational platform for future mechanistic and therapeutic studies.
- 3 February 2026
- Published by BMJ in Gut Science
- Vol. 1 (1) , e000008
Open AccessEpithelial and stromal remodelling in murine Crohn’s disease-like ileitis
Background: Inflammatory bowel disease is characterised by progressive epithelial, immune and stromal dysfunction. Human datasets yield important insights yet are inherently descriptive, requiring animal models for in vivo mechanistic interrogation. The SAMP1/YitFc (SAMP) mouse model develops spontaneous Crohn’s disease (CD)-like ileitis, allowing for the controlled manipulation of pathophysiological pathways. Objective: To define cell-specific disease-associated transcriptional changes and their translational relevance, we profiled inflamed SAMP ilea by single-nucleus RNA-sequencing (snRNA-seq) and compared identified programmes with human IBD single-cell RNA-seq datasets. Design: We performed whole-ileum snRNA-seq on SAMP (n=4) and control AKR/J (n=3) mice using the gut-optimised CitraPrep protocol, generating 58 349 high-quality nuclei across epithelial, immune and stromal lineages. We corroborated SAMP-associated changes with immunofluorescent staining, western blotting, spatial transcriptomic and human single-cell RNA-seq data. Results: We observed a primary type 2 immune phenotype in SAMP compared with AKR mice, but most transcriptional changes occurred in stromal and epithelial, not immune, cells. Stromal remodelling included increased fibroblast-derived Igf1 . In SAMP epithelium, expansion of tuft cells and emergence of SAMP-specific Pcsk6+ crypt enterocytes were observed and confirmed in patients with CD. Finally, we identified cross-compartmental changes in cell–cell signalling, including enterocyte-to-type three innate lymphoid cell communication and enhanced global Igf1 signalling. These features recapitulate both known and novel characteristics of CD, thereby extending our understanding of disease-associated multicellular networks. Conclusion: This atlas of ileitis-prone SAMP mice provides a high-resolution resource for dissecting conserved and novel mechanisms of inflammation and tissue remodelling. In this study, we uncover disease-associated transcriptional changes conserved in human CD, presenting a translational platform for future mechanistic and therapeutic studies.
- Open Access
Epithelial and stromal remodeling in murine Crohn’s disease-like ileitis
Background and Aims: Inflammatory bowel disease is characterized by progressive epithelial, immune, and stromal dysfunction. Human datasets yield important insights yet are inherently descriptive, requiring animal models for in vivo mechanistic interrogation. The SAMP1/YitFc (SAMP) mouse model develops spontaneous Crohn’s disease (CD)-like ileitis while allowing controlled manipulation of pathophysiologic pathways. To understand cell-specific disease-associated transcriptional changes, we defined the single-nucleus transcriptomes of inflamed SAMP ilea using single-nucleus RNA-sequencing (snRNA-seq). Methods: We performed whole-ileum snRNA-seq on SAMP ( n =4) and control AKR/J ( n =3) mice using the gut-optimized CitraPrep protocol, generating 58,349 high-quality nuclei across epithelial, immune, and stromal lineages. We corroborated SAMP-associated changes with immunofluorescent staining, Western blotting, spatial transcriptomic, and human single-cell RNA-sequencing data. Results: We observed a primary type 2 immune phenotype in SAMP compared to AKR mice, but most transcriptional changes occurred in stromal and epithelial, not immune, cells. Stromal remodeling included increased fibroblast-derived Igf1 . In SAMP epithelium, expansion of tuft cells and emergence of SAMP-specific Pcsk6+ crypt enterocytes were observed and confirmed in human CD patients. Finally, we identified cross-compartmental changes in cell-cell signaling, including enterocyte-to-type 3 innate lymphoid cell (ILC3) communication and enhanced global Igf1 signaling. These features recapitulate known, as well as novel, characteristics of CD and extend our understanding of disease-associated multicellular networks. Conclusion: This atlas of ileitis-prone SAMP mice provides a high-resolution resource for dissecting conserved and novel mechanisms of inflammation and tissue remodeling. Herein, we uncover disease-associated transcriptional changes conserved in human CD, presenting a translational platform for future mechanistic and therapeutic studies.
Open AccessEpithelial and stromal remodeling in murine Crohn’s disease-like ileitis
Background and Aims: Inflammatory bowel disease is characterized by progressive epithelial, immune, and stromal dysfunction. Human datasets yield important insights yet are inherently descriptive, requiring animal models for in vivo mechanistic interrogation. The SAMP1/YitFc (SAMP) mouse model develops spontaneous Crohn’s disease (CD)-like ileitis while allowing controlled manipulation of pathophysiologic pathways. To understand cell-specific disease-associated transcriptional changes, we defined the single-nucleus transcriptomes of inflamed SAMP ilea using single-nucleus RNA-sequencing (snRNA-seq). Methods: We performed whole-ileum snRNA-seq on SAMP ( n =4) and control AKR/J ( n =3) mice using the gut-optimized CitraPrep protocol, generating 58,349 high-quality nuclei across epithelial, immune, and stromal lineages. We corroborated SAMP-associated changes with immunofluorescent staining, Western blotting, spatial transcriptomic, and human single-cell RNA-sequencing data. Results: We observed a primary type 2 immune phenotype in SAMP compared to AKR mice, but most transcriptional changes occurred in stromal and epithelial, not immune, cells. Stromal remodeling included increased fibroblast-derived Igf1 . In SAMP epithelium, expansion of tuft cells and emergence of SAMP-specific Pcsk6+ crypt enterocytes were observed and confirmed in human CD patients. Finally, we identified cross-compartmental changes in cell-cell signaling, including enterocyte-to-type 3 innate lymphoid cell (ILC3) communication and enhanced global Igf1 signaling. These features recapitulate known, as well as novel, characteristics of CD and extend our understanding of disease-associated multicellular networks. Conclusion: This atlas of ileitis-prone SAMP mice provides a high-resolution resource for dissecting conserved and novel mechanisms of inflammation and tissue remodeling. Herein, we uncover disease-associated transcriptional changes conserved in human CD, presenting a translational platform for future mechanistic and therapeutic studies.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice
There are two supplementary figures. Figure S1 shows Western blot analysis of polyps from control and sildenafil treated mice, for cGMP signaling pathways (VASP, beta-catenin, AKT). Figure S2 shows RT-qPCR analysis of the mucosa and polyps from control and sildenafil treated animals for the expression of phosphodiesterases.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice
There are two supplementary figures. Figure S1 shows Western blot analysis of polyps from control and sildenafil treated mice, for cGMP signaling pathways (VASP, beta-catenin, AKT). Figure S2 shows RT-qPCR analysis of the mucosa and polyps from control and sildenafil treated animals for the expression of phosphodiesterases.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1420: A NON-SYSTEMIC PHOSPHODIESTERASE-5 INHIBITOR SUPPRESSES COLON PROLIFERATION IN MICE
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1420: A NON-SYSTEMIC PHOSPHODIESTERASE-5 INHIBITOR SUPPRESSES COLON PROLIFERATION IN MICE
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1417
Abstract 1417: A non-systemic phosphodiesterase-5 inhibitor for colon cancer prevention
Phosphodiesterase 5 inhibitors (PDE5i) are under investigation for potential repurposing as an intervention for colon cancer prevention. A drawback to conventional drugs in this class are drug-drug interactions and side-effects and that would be poorly tolerated when taken on a chronic basis for prevention. To address this issue we designed an analog of the prototypical PDE5i sildenafil by replacing the methyl group on the piperazine ring with malonic acid to reduce lipophilicity. This modification did not affect pharmacology as malonyl-sildenafil had an IC50 of 1.8 nM, but exhibited almost 100-fold reduced cell entry compared to sildenafil. Using an LC-MS/MS approach, malonyl-sildenafil was undetectable in mouse plasma 1 hour after gavage, even at a dose up to 36 mg/kg, but was readily detected in the feces collected 2-4 hours after administration. This contrasted with sildenafil that was detected in the plasma, but not in the feces. While sildenafil exhibited the established Cmax at 1-2 hr, malonyl sildenafil was not detected in the plasma up to 24 hr after an oral dose of 9 mg/kg, but continued to be shed at high levels in the feces for up to 8 hrs. Treatment of mice with malonyl-sildenafil in the drinking water for 8 days was well-tolerated, and resulted in a suppression of proliferation in the colon epithelium that is consistent with results published previously for mice treated with PDE5i. Taken together, the results demonstrate that a carboxylic acid-containing analog of sildenafil prohibits systemic delivery but maintains sufficient penetration into the colon epithelium to suppress proliferation. This highlights a novel approach to generate a first in class drug for colon cancer chemoprevention. Citation Format: Bianca N. Islam, Avelina Lee, Iryna Lebedyeva, Darren D. Browning. A non-systemic phosphodiesterase-5 inhibitor for colon cancer prevention [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1417.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1417
Open AccessAbstract 1417: A non-systemic phosphodiesterase-5 inhibitor for colon cancer prevention
Phosphodiesterase 5 inhibitors (PDE5i) are under investigation for potential repurposing as an intervention for colon cancer prevention. A drawback to conventional drugs in this class are drug-drug interactions and side-effects and that would be poorly tolerated when taken on a chronic basis for prevention. To address this issue we designed an analog of the prototypical PDE5i sildenafil by replacing the methyl group on the piperazine ring with malonic acid to reduce lipophilicity. This modification did not affect pharmacology as malonyl-sildenafil had an IC50 of 1.8 nM, but exhibited almost 100-fold reduced cell entry compared to sildenafil. Using an LC-MS/MS approach, malonyl-sildenafil was undetectable in mouse plasma 1 hour after gavage, even at a dose up to 36 mg/kg, but was readily detected in the feces collected 2-4 hours after administration. This contrasted with sildenafil that was detected in the plasma, but not in the feces. While sildenafil exhibited the established Cmax at 1-2 hr, malonyl sildenafil was not detected in the plasma up to 24 hr after an oral dose of 9 mg/kg, but continued to be shed at high levels in the feces for up to 8 hrs. Treatment of mice with malonyl-sildenafil in the drinking water for 8 days was well-tolerated, and resulted in a suppression of proliferation in the colon epithelium that is consistent with results published previously for mice treated with PDE5i. Taken together, the results demonstrate that a carboxylic acid-containing analog of sildenafil prohibits systemic delivery but maintains sufficient penetration into the colon epithelium to suppress proliferation. This highlights a novel approach to generate a first in class drug for colon cancer chemoprevention. Citation Format: Bianca N. Islam, Avelina Lee, Iryna Lebedyeva, Darren D. Browning. A non-systemic phosphodiesterase-5 inhibitor for colon cancer prevention [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1417.
- Open Access
- 1 August 2018
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 11, 323-330
Clinical utility of plecanatide in the treatment of chronic idiopathic constipation
Constipation is an important health burden that reduces the quality of life for countless millions of people. Symptom-centric therapeutics are often used to treat constipation due to unknown etiology, but in many cases, these drugs are either inadequate or have significant side effects. More recently, synthetic peptide agonists for epithelial guanylyl cyclase C (GC-C) have been developed which are effective at treating constipation in a sub-population of adult constipation patients. The first to market was linaclotide that is structurally related to the diarrheagenic enterotoxin, but this was followed by plecanatide, which more closely resembles endogenous uroguanylin. Both the drugs exhibit almost identical clinical efficacy in about 20% of patients, with diarrhea being a common side effect. Despite the potential for reduced side effects with plecanatide, detailed analysis suggests that clinically, they are very similar. Ongoing clinical and preclinical studies with these drugs suggest that treating constipation might be the tip of the iceberg in terms of clinical utility. The expression of cGMP signaling components could be diagnostic for functional bowel disorders, and increasing cGMP using GC-C agonists or phosphodiesterase inhibitors has huge potential for treating enteric pain, ulcerative colitis, and for the chemoprevention of colorectal cancer.
- 1 August 2018
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 11, 323-330
Open AccessClinical utility of plecanatide in the treatment of chronic idiopathic constipation
Constipation is an important health burden that reduces the quality of life for countless millions of people. Symptom-centric therapeutics are often used to treat constipation due to unknown etiology, but in many cases, these drugs are either inadequate or have significant side effects. More recently, synthetic peptide agonists for epithelial guanylyl cyclase C (GC-C) have been developed which are effective at treating constipation in a sub-population of adult constipation patients. The first to market was linaclotide that is structurally related to the diarrheagenic enterotoxin, but this was followed by plecanatide, which more closely resembles endogenous uroguanylin. Both the drugs exhibit almost identical clinical efficacy in about 20% of patients, with diarrhea being a common side effect. Despite the potential for reduced side effects with plecanatide, detailed analysis suggests that clinically, they are very similar. Ongoing clinical and preclinical studies with these drugs suggest that treating constipation might be the tip of the iceberg in terms of clinical utility. The expression of cGMP signaling components could be diagnostic for functional bowel disorders, and increasing cGMP using GC-C agonists or phosphodiesterase inhibitors has huge potential for treating enteric pain, ulcerative colitis, and for the chemoprevention of colorectal cancer.